Shattuck Labs, Inc. (STTK)

Shattuck Labs is a clinical-stage biotech developing novel bifunctional fusion proteins targeting cancer and autoimmune diseases, with its lead pipeline assets representing a differentiated therapeutic approach that has attracted unanimous analyst Buy ratings. The consensus price target of $14.83 implies over 100% upside from current levels, reflecting high conviction in near-term clinical catalysts. The key risk is binary clinical outcomes — pipeline failures could be severely dilutive to a stock with no earnings cushion.

• Clinical data readouts from lead pipeline programs (e.g., SL-172154 and SL-279252) expected in upcoming quarters, which could serve as major de-risking events and re-rating triggers.
• Potential partnership or licensing deal with a larger pharma player, which could provide non-dilutive capital and validate the bifunctional fusion protein platform.
• Continued cash burn discipline — any reduction in quarterly operating losses or extension of cash runway guidance could boost investor confidence and narrow the gap to the consensus price target.

• Binary clinical risk: Negative trial results for lead assets SL-172154 or SL-279252 could erase a substantial portion of market cap, given the stock is entirely pipeline-driven with no commercial revenue.
• Dilution risk: As a pre-profitability biotech, Shattuck Labs will likely require additional equity raises to fund operations, potentially diluting existing shareholders at depressed prices.
• Thin analyst coverage: With only 6–8 analysts covering the stock, a single downgrade or coverage drop could have an outsized negative impact on sentiment and price discovery.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →